Key Takeaways & Executive Findings
- •• • Single-gene knockdown of ITGA11 or ITGA6 in mixed U87 cells failed to alter phenotype or chemosensitivity, whereas combined knockdown significantly inhibited tumor growth and increased chemotherapy sensitivity, demonstrating that functional redundancy and subclonal masking necessitate multi-target intervention. • • CF5 and G11 subclones exhibited opposite phenotypes: CF5 showed stronger proliferation and chemoresistance, while G11 displayed greater motility and invasion, indicating that a single GBM cell line harbors subpopulations with divergent drug responses and metastatic potential. • • Transcriptomic profiling revealed that downregulated genes in individual clones were significantly enriched in extracellular matrix (ECM)-related gene sets, implicating ECM remodeling as a key axis of subclonal functional divergence. • • The study employed a subcutaneous tumor model for therapeutic evaluation, which, despite not fully mirroring the brain microenvironment, enabled straightforward monitoring of tumor dimensions and growth dynamics, facilitating immediate assessment of treatment efficacy.
China Biomedical & Cell Therapy Radar
Get verified English translations, SEM micrographs & open-access PDF alerts from China's leading state key laboratories delivered to your inbox every Monday at 08:00 EST.
Abstract
Glioblastoma multiforme (GBM) exhibits profound intratumoral heterogeneity that drives therapeutic resistance and recurrence. Using limiting dilution, we derived monoclonal sublines CF5 and G11 from the U87-MG GBM cell line. These subclones displayed divergent morphologies and functional phenotypes: CF5 demonstrated enhanced proliferation and chemoresistance, whereas G11 exhibited increased motility and invasion. Transcriptomic sequencing revealed extensive differential gene expression among CF5, G11, and parental U87 cells, with downregulated genes in individual clones significantly enriched in extracellular matrix (ECM)-related gene sets. ITGA11 and ITGA6 were identified as exclusive regulators of phenotype and chemotherapy sensitivity in CF5 and G11, respectively. In mixed U87 cells, single knockdown of either ITGA11 or ITGA6 failed to produce substantial phenotypic changes, but combined knockdown significantly inhibited tumor growth and increased chemosensitivity. These findings underscore that tumor heterogeneity and diverse genetic backgrounds persist even under uniform culture conditions, obscuring the functional contributions of individual genes in bulk populations. The study highlights the necessity of resolving subclonal expression patterns to accurately assign gene function and to design effective combinatorial targeted therapies. Subcutaneous tumor models, while not fully recapitulating the brain microenvironment, provided practical monitoring of tumor dynamics. This work challenges single-target therapeutic strategies and advocates for context-dependent molecular interventions in GBM.
1. Introduction
Glioblastoma multiforme (GBM) remains one of the most lethal brain tumors, with intratumoral heterogeneity driving therapeutic failure and recurrence. Standard interventions—surgical resection, radiotherapy, and temozolomide (TMZ) chemotherapy—extend short-term survival but fail to eradicate resistant subpopulations, leading to inevitable relapse. The molecular underpinnings of this heterogeneity, particularly how subclonal genetic backgrounds dictate drug response and invasive capacity, are poorly resolved. Bulk analyses obscure rare but critical subpopulations, and single-target therapies often fail because compensatory pathways or masked gene functions emerge only in specific cellular contexts.
To dissect subclonal contributions, we generated monoclonal lines CF5 and G11 from the U87-MG GBM cell line via limiting dilution. These subclones exhibited starkly divergent phenotypes: CF5 is highly proliferative and chemoresistant, while G11 is highly motile and invasive. Transcriptomic sequencing identified ITGA11 and ITGA6 as exclusive regulators of these phenotypes in CF5 and G11, respectively. Critically, in mixed U87 populations, single knockdown of either integrin produced negligible effects, whereas combined knockdown significantly suppressed tumor growth and enhanced chemosensitivity. This experimental protocol directly addresses the bottleneck of context-dependent gene function, demonstrating that therapeutic targeting must account for subclonal architecture to overcome resistance and achieve durable responses.
Loading authentic research manuscript (Pages 1–5)...
XU Daxing, JIANG Yingdi, LI Jie, GONG Lingli, YANG Zhenkun, ZHANG Bo, LI Koukou, ZOU Jian (2025). Unique gene patterns lead to distinct functional phenotypes and chemosensitivity profiles among subclones obtained from a single glioblastoma cell line. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2025091
Research & Educational Purpose Only: The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioDataare intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
Why did single knockdown of ITGA11 or ITGA6 fail to produce phenotypic changes in mixed U87 cells, while combined knockdown was effective?
In mixed U87 populations, subclonal masking and functional redundancy obscure the contributions of individual integrins. ITGA11 and ITGA6 are exclusively upregulated in distinct subpopulations (CF5 and G11, respectively), so targeting one leaves the other subpopulation intact. Combined knockdown simultaneously disrupts both subclonal drivers, leading to significant tumor growth inhibition and increased chemosensitivity. This underscores that effective therapy must address multiple subclonal targets.
What are the limitations of the subcutaneous tumor model used, and how do they impact clinical translation?
The subcutaneous model does not fully replicate the brain microenvironment, including blood-brain barrier dynamics, immune privilege, and ECM composition. However, it offers practical advantages: straightforward monitoring of tumor dimensions and growth dynamics, enabling rapid evaluation of treatment efficacy. While results may not perfectly predict intracranial responses, the model remains a valuable screening tool, as evidenced by its widespread use in breast, lung, and melanoma research.
How do the transcriptomic differences between CF5, G11, and parental U87 cells inform our understanding of GBM heterogeneity?
Transcriptomic sequencing revealed extensive differential gene expression among the three lines, with downregulated genes in individual clones significantly enriched in extracellular matrix (ECM)-related gene sets. This indicates that even under uniform culture conditions, subclones diverge in ECM remodeling pathways, which are critical for invasion, proliferation, and drug resistance. The data highlight that bulk transcriptomes mask subclonal expression patterns, and resolving these patterns is essential for accurate functional annotation.
What are the clinical implications of ITGA11 and ITGA6 as therapeutic targets in GBM?
ITGA11 and ITGA6 are elevated in GBM but their functions are obscured in mixed populations. Our findings show that targeting both integrins simultaneously is necessary to suppress tumor growth and enhance chemosensitivity. This suggests that clinical strategies must move beyond single-target agents and incorporate subclonal profiling to identify combination therapies. The study provides a rationale for developing dual-integrin inhibitors or stratified treatments based on subclonal composition.
What mechanisms underlie the divergent phenotypes of CF5 and G11 subclones?
CF5 exhibits stronger proliferative properties and chemoresistance, while G11 shows greater motility and invasion. These phenotypes are regulated exclusively by ITGA11 in CF5 and ITGA6 in G11. The distinct gene expression patterns, particularly in ECM-related pathways, drive these functional differences. This subclonal specialization likely reflects epigenetic and genetic drift during tumor evolution, contributing to overall tumor robustness and therapeutic resistance.
Related Chinese Research & Cross-Citations
miR-199a-3p suppresses Vldlr expression to promote cardiomyocyte proliferation
The proliferative capacity of cardiomyocytes is limited in adult mammals, and replacing lost tissue following acute ischemic injury is challenging. Previous studies have demonstrated that miR-199a-3p can promote cardiomyocyte proliferation, but the exact mechanism by which this occurs remains unclear, although multiple targets of miR-199a-3p have been identified. We recently showed that very-low-density-lipoprotein receptor (Vldlr) inhibits cardiomyocyte proliferation, and in this study we aim to test whether Vldlr is a functional target gene of miR-199a-3p. 3′UTR reporter assays demonstrate that miR-199a-3p directly binds to the 3′UTR of Vldlr and inhibits its translation. Overexpressing Vldlr blunts the pro-proliferative effect of miR-199a-3p on cardiomyocytes, suggesting that Vldlr is indeed a functional target of miR-199a-3p. Mechanistically, Vldlr reduces S807/811 phosphorylation of RB1, and inhibiting CDK4/6 to prevent RB1 phosphorylation can block the pro-proliferative effect of both Vldlr knockdown and miR-199a-3p, suggesting that RB1 phosphorylation is required for the cardiomyocyte proliferation induced by miR-199a-3p and Vldlr knockdown. The findings of this study reveal Vldlr as a novel functional target of miR-199a-3p in cardiomyocytes and identify RB1 as a downstream effector of cardiomyocyte proliferation. The identification of the role of the miR-199a-3p-Vldlr-RB1 axis in cardiomyocyte proliferation may provide potential therapeutic targets for cardiac regenerative medicine.
A positive feedback loop between FOSB and miR-133b controls colon cancer cell proliferation
FOSB, a member of the FOS gene family, forms heterodimers with JUN family proteins to engage in diverse cellular processes. Its biological impacts vary among different types of tumors, yet its specific function in colon cancer (CC) remains ambiguous. In this study, quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC) are applied to measure FOSB expression levels, followed by an analysis of the association between FOSB expression and patients’ clinical parameters. In vitro experiments are performed to assess cell proliferation, including growth rate, cell cycle distribution, and apoptosis. A subcutaneous xenograft model in nude mice is utilized to monitor tumor growth in vivo. Additionally, chromatin immunoprecipitation (ChIP) and luciferase reporter assays are conducted to dissect the interactions among FOSB, miR-133b, and POU2F1. The results indicate that FOSB expression is downregulated in CC tissues relative to normal controls. Overexpression of FOSB suppresses proliferation and promotes apoptosis in CC cells. Mechanistically, FOSB binds to the promoter region of miR-133b, enhancing its transcription and subsequently repressing POU2F1 expression. Notably, decreased POU2F1 expression also alleviates the transcriptional repression of the FOSB promoter region, establishing a FOSB-miR-133b-POU2F1 feedback loop that inhibits CC proliferation. In summary, our findings suggest that FOSB acts as a tumor suppressor gene in CC and may exert its inhibitory effects on CC growth via the FOSB-miR-133b-POU2F1 feedback loop.
Reduced expression of the PER2 protein contributes to β1-AA-induced cardiac autophagy rhythm disorders
Heart failure may be linked to fluctuations in the rhythm of autophagy in cardiomyocytes throughout the day. Circadian rhythms depend on the regulation of core biological clock proteins, with PER2 playing a crucial role. Our previous research confirmed that the presence of β1-adrenergic receptor autoantibodies (β1-AAs) could inhibit myocardial autophagy, leading to cell death and heart failure. However, it remains unclear whether β1-AA induces cardiac autophagy rhythm disorders by affecting PER2 expression. In this study, we find that β1-AA disrupts the autophagy rhythm in cardiomyocytes, which is primarily indicated by decreased expression of the autophagy marker protein LC3. β1-AA disrupts the rhythmic expression of the PER2 protein in myocardial cells, which is manifested mainly by a decrease in PER2 protein expression. Metoprolol is used to verify that the β1-adrenergic receptor contributes to the reduction in the Per2 protein caused by β1-AA. Knockdown of Per2 with lentivirus reduces the inhibition of LC3 expression caused by β1-AA, whereas overexpression of Per2 in cardiomyocytes using lentivirus significantly restores the β1-AA-induced decrease in LC3 expression. Moreover, mTORC1 activation is found to participate in β1-AA-induced autophagy inhibition in cardiomyocytes after pretreatment with the mTORC1 inhibitor rapamycin. Furthermore, the decreased expression of the PER2 protein caused by β1-AA disrupts the myocardial autophagy rhythm by promoting mTORC1 activation through lentiviruses that knock down or overexpress the Per2 gene. This study provides an experimental basis for the precise treatment of cardiovascular diseases from the perspective of biological rhythm.
A protein-RNA complex orchestrated by EMB1006, EMB1270, EMB976, and CFM2 facilitates clpP1 intron 2 splicing in Arabidopsis chloroplasts
In Arabidopsis, the PPR proteins EMB1006, EMB1270, and EMB976 are all essential for the splicing of plastid clpP1 intron 2 (clpP1.2), although each also targets other distinct RNAs. The precise mechanism underlying their co-ordinated action in clpP1.2 splicing remains unclear. In this study, RNA electrophoretic mobility shift assays, guided by PPR code prediction, confirm that EMB1006 specifically binds to a sequence near the 3′ end of clpP1 exon 2. Additionally, immunoprecipitation coupled with mass spectrometry reveals that EMB1006 forms a complex with EMB1270, EMB976, and CFM2. Direct interactions between EMB1006 and EMB1270 or CFM2 are further supported by yeast two-hybrid (Y2H) and semi-in vivo pull-down assays. However, no direct interactions between EMB976 and EMB1006, CFM2 or EMB1270 are detected by Y2H. Based on these findings and previous evidence that EMB1270 binds to clpP1 intron 2 and interacts with CFM2, we propose a model in which EMB1006 and EMB1270 bind to distinct sites on clpP1 pre-mRNA. Together with CFM2 and possible indirect association with EMB976, they assemble into a protein-RNA complex that facilitates the splicing of clpP1.2 in chloroplasts.
Tanshinones from Salvia miltiorrhiza alleviate ulcerative colitis via reprogramming the gut microbiota-metabolite axis
The anti-inflammatory properties of the traditional herb Salvia miltiorrhiza Bunge are well-established, yet its precise mechanism of action in ulcerative colitis (UC) remains unclear. Herein, we evaluate the therapeutic potential of four major tanshinones–tanshinone IIA (Tan IIA), miltirone, neocryptotanshinone, and dihydrotanshinone I–in a murine dextran sulfate sodium (DSS)-induced colitis model. Our results show that tanshinones effectively alleviate disease severity, suppress systemic and local inflammation, and restore intestinal barrier integrity. Integrated multi-omics analysis reveals that the therapeutic efficacy originates from a comprehensive reprogramming of the gut microbiota-metabolite axis. Specifically, tanshinones reverse colitis-associated dysbiosis and rectify metabolic disturbances in linoleic acid metabolism, bile acid biosynthesis, and amino acid utilization. Correlation network analysis identifies key functional modules linking beneficial microbes (e.g., Akkermansia) to anti-inflammatory lipid mediators and associating pathobionts (e.g., Desulfovibrio) with disrupted bile acid metabolism. Notably, supplementation with Akkermansia muciniphila synergizes with Tan IIA to amplify barrier restoration and metabolic normalization. Our findings establish that tanshinones ameliorate UC through microbiota-driven metabolic reprogramming, wherein the restructured microbial community actively shapes a therapeutic metabolic output. This work elucidates a metabolite-mediated mechanism of action and positions tanshinones as promising microbiome-targeting therapeutics for inflammatory bowel disease.
Distinct miR319a identified from Persicaria chinensis mediates cross-kingdom suppression of cervical cancer by targeting ITGA3
Persicaria chinensis, a well-known traditional Chinese medicinal herb that is both edible and medicinal, has been widely acknowledged for its therapeutic effects, such as anti-inflammatory, antioxidant, and antitumor activities. However, the role of miRNAs from this plant in the cross-kingdom regulation of human diseases has not been investigated. In this study, we analyze the miRNA expression profile of P. chinensis using high-throughput sequencing and identify a total of 673 miRNAs, including 422 novel miRNAs that are unique to this plant and 251 conserved miRNAs. Among the conserved miRNAs, pch-miR319a is found to be the most abundant. Moreover, food-oriented pch-miR319a accumulates in the uterus and tumors and exhibits a rich repertoire of target genes within cancer-related pathways, demonstrating significant cross-kingdom regulatory potential. Utilizing the dual-luciferase reporter gene assay, we demonstrate that pch-miR319a from P. chinensis targets the Itga3 gene, which is associated with cervical cancer progression. Overexpression of pch-miR319a significantly decreases the viability, migration, and induces apoptosis of HeLa cervical cancer cells in vitro. Moreover, in a syngeneic mouse tumor model of cervical cancer, treatment with pch-miR319a effectively inhibits tumor growth and downregulates the expressions of ITGA3 and the proliferation marker Ki-67. Our study highlights the potential of pch-miR319a from P. chinensis as a novel therapeutic agent for cervical cancer by targeting ITGA3 and provides new insights into the cross-kingdom regulatory mechanisms of plant miRNAs in human diseases.